The Apex Times
Above the Noise
Business Wire
BusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex TimesBusinessJensen Huang’s “Buy at a Discount” remark returns to focus as Nvidia shares rise and an AI basket gainsThe Apex TimesBusinessAMD says it is expanding its AI infrastructure footprint in Saudi ArabiaThe Apex TimesBusinessVerizon readies network resources as Tropical Storm Edouard nearsThe Apex TimesBusinessNvidia shares show a rare trading pattern, underscoring how investors are rethinking semiconductor correlationsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipelineThe Apex TimesBusinessNvidia backs MediaTek with $3.5 billion convertible-bond deal, indicating a push for local AIThe Apex TimesBusinessBoeing to resume contract talks with engineers, as strike threat remains on the tableThe Apex TimesBusinessFTC and 22 states sue Amazon, alleging it manipulated online ad auctionsThe Apex TimesBusinessAlphabet’s Google says Gemini-powered “Teamwork” agents solved open math, built a CPU simulator, and improved core open-source librariesThe Apex TimesBusinessKKR’s “mini Berkshire” push shows early results as it sells USI assets for about $17 billionThe Apex TimesBusinessDeere shares rise after Baird upgrade to OutperformThe Apex TimesBusinessReport: Exxon Mobil joins bidders for Shell’s U.S. chemicals assets, a potential shift for XOM’s refining-and-chemicals outlookThe Apex Times
Back to front
Pfizer lifts its 2026 outlook as declining Covid-19 revenue proves less damaging than expected
The Apex Times

THE APEX TIMES

Business/The Apex Times/Aug 4, 12:47 PM EDT

Pfizer lifts its 2026 outlook as declining Covid-19 revenue proves less damaging than expected

The drugmaker said its Covid-19 portfolio is no longer expected to drag results as much as previously thought, and is pointing to revenue resilience from its established specialty franchises.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Pfizer is indicating that the downturn in its Covid-19 business is not unfolding as severely as it had feared, and it is moving to raise its 2026 guidance, according to a report published by Yahoo Finance.

The adjustment is being framed as a response to the trajectory of Covid-19 products, whose sales have fallen sharply as the pandemic phase fades and demand normalizes. Pfizer’s management is effectively treating the Covid-19 decline as a contained headwind rather than a dominant factor for the next year’s financial targets, the report said.

In positioning for the revised outlook, Pfizer is also leaning on its specialty pipeline and established branded medicines. The report specifically points to Eliquis, a long-running oral anticoagulant, as a key contributor to the company’s ability to defend overall revenue during a post-Covid transition.

That emphasis reflects a broader post-pandemic reality for large pharmaceutical companies: as emergency-era demand drops away, investors and analysts increasingly focus on durability in chronic-care franchises, the speed of new launches, and the degree to which portfolio shifts can offset declines elsewhere.

Pfizer’s 2026 guidance lift is therefore less about a single program and more about narrative control, with the company attempting to demonstrate that it can steer through revenue pressure without a major deterioration elsewhere in its portfolio.

The report does not provide, in the information available here, the size of the guidance increase, the specific financial line items (such as revenue, adjusted earnings, or cash flow), or the underlying assumptions that support the change, such as updated volume, pricing, or reimbursement outlooks for Covid-related products.

It also does not clarify how the company is treating cross-currents like ongoing competitive dynamics in anticoagulation and other specialty categories, or the timing of any material pipeline milestones that could be influencing the 2026 view.

As Pfizer’s planning updates are communicated, the market will likely focus on whether the guidance revision is backed by more detailed segment-level drivers and forward visibility, rather than just a high-level directional improvement.

Why It Matters

  • A guidance increase can change investor expectations for how resilient Pfizer’s specialty franchises are in a post-Covid demand environment.
  • The market will look for confirmation that Covid-19 revenue is becoming a manageable headwind rather than a structural drag.
  • Emphasis on Eliquis and similar brands underscores how chronic-care leadership may determine earnings stability more than episodic products going forward.
  • If Pfizer’s revised targets hold, it could reduce pressure for aggressive cost cutting or portfolio reshaping tied to Covid-era volatility.

Sources

Key Facts

  • Pfizer is moving to raise its 2026 guidance, according to a report carried by Yahoo Finance.
  • The guidance change is tied to the performance and expected trajectory of Pfizer’s Covid-19 business.
  • The report characterizes the Covid-19 sales decline as less damaging than previously anticipated.
  • Pfizer is citing revenue durability from established products, including Eliquis.
  • Specific guidance figures and the detailed assumptions behind the change were not provided in the information available here.

Healthcare Related

Pfizer lifts its 2026 outlook as declining Covid-19 revenue proves less damaging than expected | The Apex Times